It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Mps one binder 2 (MOB2) regulates the NDR kinase family, however, whether and how it is implicated in cancer remain unknown. Here we show that MOB2 functions as a tumor suppressor in glioblastoma (GBM). Analysis of MOB2 expression in glioma patient specimens and bioinformatic analyses of public datasets revealed that MOB2 was downregulated at both mRNA and protein levels in GBM. Ectopic MOB2 expression suppressed, while depletion of MOB2 enhanced, the malignant phenotypes of GBM cells, such as clonogenic growth, anoikis resistance, and formation of focal adhesions, migration, and invasion. Moreover, depletion of MOB2 increased, while overexpression of MOB2 decreased, GBM cell metastasis in a chick chorioallantoic membrane model. Overexpression of MOB2-mediated antitumor effects were further confirmed in mouse xenograft models. Mechanistically, MOB2 negatively regulated the FAK/Akt pathway involving integrin. Notably, MOB2 interacted with and promoted PKA signaling in a cAMP-dependent manner. Furthermore, the cAMP activator Forskolin increased, while the PKA inhibitor H89 decreased, MOB2 expression in GBM cells. Functionally, MOB2 contributed to the cAMP/PKA signaling-regulated inactivation of FAK/Akt pathway and inhibition of GBM cell migration and invasion. Collectively, these findings suggest a role of MOB2 as a tumor suppressor in GBM via regulation of FAK/Akt signaling. Additionally, we uncover MOB2 as a novel regulator in cAMP/PKA signaling. Given that small compounds targeting FAK and cAMP pathway have been tested in clinical trials, we suggest that interference with MOB2 expression and function may support a theoretical and therapeutic basis for applications of these compounds.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Liaoning Cancer Hospital & Institute, Department of Neurosurgery, Cancer Hospital of China Medical University, Shenyang, China (GRID:grid.459742.9) (ISNI:0000 0004 1798 5889); Dalian Medical University Cancer Center, Institute of Cancer Stem Cell, Dalian, China (GRID:grid.411971.b) (ISNI:0000 0000 9558 1426)
2 Dalian Medical University Cancer Center, Institute of Cancer Stem Cell, Dalian, China (GRID:grid.411971.b) (ISNI:0000 0000 9558 1426)
3 the First Affiliated Hospital to Dalian Medical University, The First Department of Ultrasound, Dalian, China (GRID:grid.452435.1)
4 Liaoning Cancer Hospital & Institute, Department of Neurosurgery, Cancer Hospital of China Medical University, Shenyang, China (GRID:grid.459742.9) (ISNI:0000 0004 1798 5889)
5 Affiliated Zhongshan Hospital of Dalian University, Department of Oncology, Dalian, China (GRID:grid.459353.d) (ISNI:0000 0004 1800 3285)
6 Liaoning Cancer Hospital & Institute, Central laboratory, Cancer Hospital of China Medical University, Shenyang, China (GRID:grid.459742.9) (ISNI:0000 0004 1798 5889)